Login / Signup

Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort.

Montserrat AlegretOscar Sotolongo-GrauEster Esteban de AntonioAlba Pérez-CordónAdelina OrellanaAna EspinosaSilvia GilDaniel JiménezGemma OrtegaAngela SanabriaNatalia RobertoIsabel HernándezMaitee Rosende-RocaJuan Pablo TartariEmilio Alarcon-MartinItziar de RojasLaura MontrrealXavier MoratóAmanda CanoDorene M RentzLluís TárragaAgustín RuizSergi ValeroMarta MarquiéMercè Boada
Published in: Alzheimer's research & therapy (2022)
FACEmemory is a promising tool for detecting memory deficits sensitive to early-onset AD, but it also allows the detection of memory-impaired cases due to other etiologies. Our findings suggest that FACEmemory scoring can detect the AD endophenotype and that it is also associated with AD-related changes in MRI and CSF in patients with EOMCI. The computerized FACEmemory tool might be an opportunity to facilitate early detection of MCI in younger people than 65, who have a growing interest in new technologies.
Keyphrases